| 01.18.24 | CG Oncology aims for $209M IPO; BridgeBio raises $1.25B for Pfizer showdown

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

10 Monate vor

Html
Text


A message from MASS

Today’s Big News

Jan 18, 2024

CG Oncology aims for $209M IPO, as more biotechs eye path to public markets

BridgeBio taps investors for $1.25B to fund showdown with Pfizer

Surrozen stops IBD program due to dose concerns and competition

Mushroom-derived drug posts improved survival data in Golden Biotech’s pancreatic cancer trial

Open science contest uses AI to ID possible hits for Parkinson’s, side-stepping 'patent-driven approach'


A message from BD&L Summit

Featured

CG Oncology aims for $209M IPO, as more biotechs eye path to public markets

By James Waldron

CG Oncology is hoping to raise $209 million from its upcoming IPO, blazing a trail to the public markets that seems to be enticing more biotechs in the first month of the year.

BridgeBio taps investors for $1.25B to fund showdown with Pfizer

By Nick Paul Taylor

BridgeBio Pharma is building a war chest for its showdown with Pfizer. Facing a deep-pocketed rival, the biotech has struck a set of financing deals worth up to $1.25 billion to support an anticipated launch and a schedule of phase 3 readouts for other assets.

Surrozen stops IBD program due to dose concerns and competition

By Max Bayer

Surrozen has halted the development of its clinical-stage IBD med, due in part to trouble with dose safety. The company says that "several" patients at higher dose levels experienced asymptomatic increases in liver enzymes.

Mushroom-derived drug posts improved survival data in Golden Biotech’s pancreatic cancer trial

By Nick Paul Taylor

Golden Biotechnology has shared updated data on its mushroom-derived drug candidate in metastatic pancreatic cancer, linking first-line use of the molecule to median overall survival (OS) of 14.1 months.

Whitepaper: Scaling to New Heights: Robust Scale Up from Shake Flask to Commercial AAV Manufacturing for All Patient Populations

This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.

Open science contest uses AI to ID possible hits for Parkinson’s, side-stepping 'patent-driven approach'

By Helen Floersh

An AI-driven open science competition held by a Canadian nonprofit and sponsored by the Michael J. Fox Research Foundation has announced the discovery of molecules that could someday lead to new treatments for Parkinson’s disease.

Bayer CEO Bill Anderson makes his mark with major restructuring, 'significant' job cuts

By Angus Liu

Bayer is launching a sweeping business overhaul that will “come at the expense of many managerial employees,” as the German conglomerate sees “no viable alternative.”

Apple begins selling pulse ox-free Apple Watches after reinstated import ban

By Andrea Park

To comply with the now-reinstated import ban, newly sold Series 9 and Ultra 2 Apple Watch models in the U.S. will no longer offer the blood oxygen measurement feature.

Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space

By Joseph Keenan

Immunotherapeutic vaccine developer Vaxxinity is partnering with the University of Central Florida to advance space medicine research.

Cancer death rate continues to decline but new cases expected to top 2 million this year, study finds

By Heather Landi

Cancer deaths in the United States are falling, with more than 4 million fewer deaths since 1991. But, this progress is jeopardized by increasing incidence for 6 of the top 10 cancers as the projected number of new diagnoses now tops 2 million for the first time, according to new data from the American Cancer Society.

Fierce podcasts

Don’t miss an episode

'Podnosis': Improving the diversity of voice tech

A growing number of companies are introducing diverse voices to their virtual assistants or speech synthesis systems: Apple’s Siri, Amazon’s Polly, Meta’s Voicebox. But what about diversity of voices in healthcare, where the stakes are higher?

'The Top Line': The year in biotech

'The Top Line': A closer look at the Fierce 50


A message from Promab Biotechnologies

Resources

Whitepaper

Digital Health Innovation: From Concept to Commercialization

The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process.

Developing and Manufacturing Drugs with HPAPIs

Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient.

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Presented by Blue Matter, strategic consultants in the life sciences